Cure8 research brief
This study identifies a new molecular pathway (JAK2–STAT4–AK4–mtDNA) linked to inflammatory macrophage activity in experimental colitis and presents a plant-derived alkaloid mixture (TAMR) that modulates that pathway. That could point to new drug targets or lead compounds for ulcerative colitis.
Researchers in IBD immunology and drug discovery; translational clinicians interested in novel preclinical UC therapeutics.
A lab study in mice and cell models reports that total alkaloids extracted from Menispermi Rhizoma (TAMR) reduced colitis-like inflammation in a DSS mouse model and shifted macrophage polarization.
The authors used RNA sequencing and molecular experiments to trace the effect to inhibition of the JAK2–STAT4 signaling cascade and reduced expression of AK4, which they link to lower mitochondrial DNA (mtDNA) synthesis in inflammatory macrophages.
The work is preclinical and mechanistic: experiments were done in mice (DSS colitis) and in RAW264.7 macrophage cells, including STAT4 knockdown/overexpression and ChIP to show STAT4 binding to the Ak4 promoter.
The paper identifies a JAK2–STAT4–AK4–mtDNA axis as a potential therapeutic target and presents TAMR as a candidate alkaloid mixture for further study. This is not clinical evidence that TAMR is safe or effective in people with ulcerative colitis.
It provides a rationale for additional preclinical work and, if supported by safety studies, eventual early-phase clinical testing.
Preclinical study in mice and cell lines. Not evidence of safety or efficacy in humans.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of Competing Interest ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study introduces a novel preclinical therapeutic approach that selectively degrades HDAC6 and reduced inflammation in a mouse model of colitis, suggesting a potential new drug-discovery avenue relevant to ulcerative...
The project investigates how TNFR1 and TNFR2 differently control epithelial repair in the colon—mechanisms that may explain why many patients on anti‑TNF biologics do not achieve lasting mucosal healing and could point...
Researchers are developing a novel drug-discovery approach to degrade GATA3, a protein that drives Th2 inflammation in ulcerative colitis. New therapies that more directly target immune drivers could eventually help...
